论文部分内容阅读
目的 :对心房颤动射频消融术后多种药物抗凝治疗的临床疗效和安全性进行对比研究。方法 :将入组的确诊心房颤动患者112例,按随机数字表分为A组(37例)、B组(40例)和C组(35例)。采用射频消融术治疗后,A组、B组和C组分别口服华法林片、达比加群酯胶囊和利伐沙班进行抗凝治疗,疗程90 d,比较各组患者的疗效、安全性和不良反应的发生情况。结果:B组疗效与A组和C组相当,差异均无统计学意义(P﹥0.05),C组疗效优于A组,差异有统计学意义(P﹤0.05);B组和C组的出血发生率均低于A组,差异均有统计学意义(P﹤0.05),B组和C组之间的安全性差异无统计学意义(P﹥0.05);3组患者在治疗过程中均出现轻微的其他不良反应,发生率差异无统计学意义(P﹥0.05)。结论:达比加群酯和利伐沙班在心房颤动射频消融术后的抗凝治疗中,疗效优于或等同华法林,安全性较优,临床应用方便,值得在临床上推广。
Objective: To compare the clinical efficacy and safety of multiple drug anticoagulation therapy after atrial fibrillation radiofrequency catheter ablation. Methods: A total of 112 patients with atrial fibrillation were enrolled and divided into group A (n = 37), group B (n = 40) and group C (n = 35) according to random number table. After radiofrequency ablation, A, B and C groups were treated with warfarin, dabigatran etexilate capsules and rivaroxaban for anticoagulant therapy for 90 days. The curative effect and safety of each group were compared Sex and adverse reactions occurred. Results: The curative effect in group B was similar to those in group A and group C (P> 0.05), and the curative effect in group C was better than that in group A (P <0.05). In group B and group C (P <0.05). There was no significant difference in safety between group B and group C (P> 0.05). In the three treatment groups There were slight other adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion: The dabigatran etexilate and rivaroxaban are superior to or equivalent to warfarin in anticoagulant therapy after atrial fibrillation radiofrequency catheter ablation, which is safe and convenient in clinical application and worthy of clinical application.